EP3219329A1 — Combinations of copanlisib
Assigned to Bayer Pharma AG · Expires 2017-09-20 · 9y expired
What this patent protects
The present invention relates to : * combinations of : component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2) as defined herein, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ; component B : one …
USPTO Abstract
The present invention relates to : * combinations of : component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2) as defined herein, or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ; component B : one or more IRAK4-inhibiting compounds of general formula (I) as defined herein,or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof ; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route ; * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer ; and * a kit comprising such a combination.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.